Abstract
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Betacoronavirus / isolation & purification
-
COVID-19
-
Cardiovascular Diseases / prevention & control*
-
Clinical Trials as Topic
-
Coronavirus Infections / diagnosis*
-
Coronavirus Infections / virology
-
Cytokines / metabolism
-
Humans
-
Inflammasomes / metabolism
-
Myocarditis / prevention & control
-
NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors
-
NLR Family, Pyrin Domain-Containing 3 Protein / metabolism*
-
Nitriles / therapeutic use
-
Pandemics
-
Pneumonia, Viral / diagnosis*
-
Pneumonia, Viral / virology
-
Prognosis
-
SARS-CoV-2
-
Venous Thromboembolism / prevention & control
-
ortho-Aminobenzoates / therapeutic use
Substances
-
Cytokines
-
Inflammasomes
-
NLR Family, Pyrin Domain-Containing 3 Protein
-
Nitriles
-
ortho-Aminobenzoates
-
dapansutrile
-
tranilast